Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chinese Academy of Sciences PTP1B compound 6h: sourced facts only. name: "Biological evaluation identified the 4-fluorophenylalanine derivative 6h as the most potent PTP1B inhibitor (IC50 = 32.70 μM) with a selectivity index of 7.0 over TCPTP." [PMID:42320200]; target: "Biological evaluation identified the 4-fluorophenylalanine derivative 6h as the most potent PTP1B inhibitor (IC50 = 32.70 μM) with a selectivity index of 7.0 over TCPTP." [PMID:42320200]; developer: "State Key Laboratory of Phytochemistry and Natural Medicines, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China; University of Chinese Academy of Sciences, Beijing, 100049, China." [PMID:42320200]; stage: "Moreover, 6h significantly reduced random and fasting blood glucose levels in STZ-induced diabetic mice." [PMID:42320200]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chinese Academy of Sciences PTP1B compound 6h.